EP2526199A4 - Verfahren zur erzeugung von zinkfingernukleasen mit veränderter wirkung - Google Patents

Verfahren zur erzeugung von zinkfingernukleasen mit veränderter wirkung

Info

Publication number
EP2526199A4
EP2526199A4 EP11735277.3A EP11735277A EP2526199A4 EP 2526199 A4 EP2526199 A4 EP 2526199A4 EP 11735277 A EP11735277 A EP 11735277A EP 2526199 A4 EP2526199 A4 EP 2526199A4
Authority
EP
European Patent Office
Prior art keywords
methods
zinc finger
catalytic activity
zfn
altered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11735277.3A
Other languages
English (en)
French (fr)
Other versions
EP2526199A2 (de
Inventor
Iii Carlos F Barbas
Jing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP2526199A2 publication Critical patent/EP2526199A2/de
Publication of EP2526199A4 publication Critical patent/EP2526199A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP11735277.3A 2010-01-22 2011-01-21 Verfahren zur erzeugung von zinkfingernukleasen mit veränderter wirkung Withdrawn EP2526199A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29759810P 2010-01-22 2010-01-22
US32903510P 2010-04-28 2010-04-28
PCT/US2011/022154 WO2011091324A2 (en) 2010-01-22 2011-01-21 Methods of generating zinc finger nucleases having altered activity

Publications (2)

Publication Number Publication Date
EP2526199A2 EP2526199A2 (de) 2012-11-28
EP2526199A4 true EP2526199A4 (de) 2013-08-07

Family

ID=44307625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11735277.3A Withdrawn EP2526199A4 (de) 2010-01-22 2011-01-21 Verfahren zur erzeugung von zinkfingernukleasen mit veränderter wirkung

Country Status (2)

Country Link
EP (1) EP2526199A4 (de)
WO (1) WO2011091324A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660642A (zh) * 2012-04-24 2012-09-12 西北农林科技大学 一种筛选锌指蛋白的筛选系统
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
US20210047633A1 (en) * 2017-03-29 2021-02-18 Editas Medicine, Inc. Selection methods
WO2018227114A1 (en) 2017-06-09 2018-12-13 Editas Medicine, Inc. Engineered cas9 nucleases
CN108118059B (zh) * 2017-12-30 2021-03-19 苏州金唯智生物科技有限公司 一种改进的启动子及其组成的载体和应用
JP2022547699A (ja) * 2019-09-12 2022-11-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ライブラリーのスクリーニング方法
EP4143304A2 (de) 2020-04-28 2023-03-08 Intellia Therapeutics, Inc. Verfahren zur in-vitro-zellfreisetzung
EP4242237A1 (de) * 2020-11-06 2023-09-13 Editforce, Inc. Foki-nukleasedomänenvariante
TW202239959A (zh) 2020-12-23 2022-10-16 美商英特利亞醫療公司 用於減少細胞中hla-a之組合物及方法
JP2024501246A (ja) 2020-12-23 2024-01-11 インテリア セラピューティクス，インコーポレイテッド 細胞中のｃｉｉｔａを遺伝子修飾するための組成物及び方法
CA3206484A1 (en) 2020-12-30 2022-07-07 Intellia Therapeutics, Inc. Engineered t cells
CR20230534A (es) 2021-04-17 2024-02-12 Intellia Therapeutics Inc Composiciones de nanopartículas lipídicas
IL307740A (en) 2021-04-17 2023-12-01 Intellia Therapeutics Inc DNA-dependent protein kinase inhibitors and their compositions and uses
AU2022257050A1 (en) 2021-04-17 2023-11-30 Intellia Therapeutics, Inc. Lipid nanoparticle compositions
WO2023205148A1 (en) 2022-04-19 2023-10-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2023245108A2 (en) 2022-06-16 2023-12-21 Intellia Therapeutics, Inc. Compositions and methods for reducing mhc class i in a cell
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139898A2 (en) * 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Variant foki cleavage half-domains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087341A2 (en) * 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20090042186A1 (en) * 2005-05-06 2009-02-12 Alexander Mankin Mapping new sites for antibiotic action in the ribosome
EP2568048A1 (de) * 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Verfahren zur Veränderung des Genoms einer Zelle von Einkeimblättrigen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139898A2 (en) * 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Variant foki cleavage half-domains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Structure-Based Engineering of the FokI DNA Cleavage Domain in the Context of a Chimeric Endonuclease: Towards Maximally Efficient ''Gene Editing'' Therapy", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 9, 1 May 2004 (2004-05-01), pages 272, XP004635080, ISSN: 1525-0016 *
JING GUO ET AL: "Directed Evolution of an Enhanced and Highly Efficient FokI Cleavage Domain for Zinc Finger Nucleases", JOURNAL OF MOLECULAR BIOLOGY, vol. 400, no. 1, 4 May 2010 (2010-05-04), pages 96 - 107, XP055065197, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2010.04.060 *
MANI M ET AL: "Design, engineering, and characterization of zinc finger nucleases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 335, no. 2, 23 September 2005 (2005-09-23), pages 447 - 457, XP027230194, ISSN: 0006-291X, [retrieved on 20050811], DOI: 10.1016/J.BBRC.2005.07.089 *
URNOV F D ET AL: "Highly efficient endogenous human gene correction using designed zinc-finger nucleases", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 435, no. 7042, 2 June 2005 (2005-06-02), pages 646 - 651, XP002411069, ISSN: 0028-0836, DOI: 10.1038/NATURE03556 *

Also Published As

Publication number Publication date
EP2526199A2 (de) 2012-11-28
WO2011091324A8 (en) 2012-08-30
WO2011091324A2 (en) 2011-07-28
WO2011091324A3 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
EP2526199A4 (de) Verfahren zur erzeugung von zinkfingernukleasen mit veränderter wirkung
MX2018007519A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
NZ750938A (en) Regulation of gene expression using engineered nucleases
WO2018129368A3 (en) Methods of assessing nuclease cleavage
MY164783A (en) Reactor systems
WO2012166997A3 (en) Electrochemical reactor and process
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
TN2014000493A1 (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3613852A3 (de) Beurteilung und verbesserung einer nukleasespaltungsspezifität
WO2010107493A3 (en) Modification of cxcr4 using engineered zinc finger proteins
MX353621B (es) Variantes de alfa-amilasa.
MX351043B (es) Metodos para modificacion genomica.
MX336846B (es) Alteracion genomica dirigida.
MX370134B (es) Enzimas de cetol-acido reductoisomerasa y metodo de uso.
WO2013059582A3 (en) Small molecule inhibitors of histone deacteylases
EP2667435A4 (de) Graphit/kohlenstoff-mischmaterial, kohlenstoffmaterial für batterieelektroden und batterie
MX349801B (es) Sustratos de enzimas de ácido nucleico.
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2012061022A3 (en) Use of copper-nickel catalyst for dehalogenation of chlorofluorocompounds
SG195170A1 (en) Methods of treating or preventing rheumatic disease
WO2012109527A3 (en) Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
IN2014CN01171A (de)
WO2013184645A3 (en) Novel phenyl glyoxal probes
WO2012007848A3 (en) Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
Haest et al. Erratum to" Dechlorination kinetics of TCE at toxic TCE concentrations: Assessment of different models"[Water Research 44 (2010) 1]

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120813

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130710

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/14 20060101ALI20130704BHEP

Ipc: C12Q 1/34 20060101AFI20130704BHEP

Ipc: C12N 15/55 20060101ALI20130704BHEP

Ipc: C07K 14/47 20060101ALN20130704BHEP

Ipc: C12N 15/10 20060101ALN20130704BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20140917